Chen L, et al. - As a part of this study, researchers probed into the role and mechanism of miR-199a in regulating prostate cancer resistance. Results displayed that the downregulation of miR-199a contributed towards paclitaxel (PTX) resistance in prostate cancer. Yamaguchi sarcoma viral homolog 1 (YES1) was found to mediate the regulation of miR-199a in prostate cancer PTX resistance. This miR-199a replacement therapy exhibited the potential to overcome PTX resistance.